Able Laboratories to Announce 2002 Second Quarter Financial Results on Wednesday, July 31, 2002.Business Editors & Health/Medical Writers SOUTH PLAINFIELD, N.J.--(BW HealthWire)--July 26, 2002 Able Laboratories (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABLA ABLA Asia Business Leader Awards ABLA American Belgian Laekenois Association ABLA American Blind Lawyers Association ABLA American Business Law Association ABLA Asheville Business Leaders Association (Asheville, NC) ) (BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). :ABRX), today announced that it will release its 2002 second quarter financial results prior to market opening on July 31, 2002. Coinciding with this announcement, the Company has scheduled a conference call and webcast at 10:30 a.m. Eastern Time, or 7:30 a.m. Pacific Time. To participate in the conference call, please call 888/803-8295. A telephone replay will be made available for 48 hours following the call by dialing 800/642-1687 and entering reservation number 5067818. Individuals interested in listening to the conference call via the Internet may do so by visiting the web site http://www.ablelabs.com. A replay will be made available on the web site for 90 days. Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Since March 2001, Able has received 14 ANDA ANDA abbr. abbreviated new drug application approvals. The Company has completed its transition to focus its activities on generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. development, manufacturing and sales. Further information on Able may be found on the Company's web site, www.ablelabs.com Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by Able Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and involve risks and uncertainties. For example, statements about the Company's operations, capital-raising transactions and financial accounting, the current or expected market size for its products, the success of current or future product offerings, the research and development efforts and the Company's ability to file for and obtain U.S. Food and Drug Administration approvals for future products, are forward-looking statements. Forward-looking statements are merely the Company's current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings and approvals will be completed and obtained as anticipated. For a description of additional risks, and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001 and its Form 10-Q Form 10-Q See 10-Q. for the three months ended March 31, 2002. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion